|
|
 |

January News
Myelin News
January 27th, 2012
Family of ALD sufferers pledge to raise money for The Myelin Project
Two brothers are following in their father’s footsteps and becoming trustees of a global charity. Charles and Harry Fynn of Bournemouth have pledged to throw themselves into fundraising for The Myelin Project and to help raise awareness of its work. It is a cause close to their heart for a very good reason as both young men carry the rogue gene for ALD (adrenoleukodystrophy). It has been described as a “cerebral timebomb” which was once considered fatal. That was until the parents of an American sufferer, Lorenzo Odone, refused to accept the prognosis that there was no hope for their son. The outcome of their search for a cure was a special therapy that became known as Lorenzo’s Oil. READ MORE...
January 23rd, 2012
Metabolites Involved in Chronic Pain
Untargeted metabolic profiling implicates a new suite of metabolites that may be involved in nerve damage-induced pain.
By Jeffrey M. Perkel | January 22, 2012
An analysis of the metabolic profile of a rat model of chronic pain has identified novel dysregulated metabolites that may underlie the condition, according to a study published today (January 22) in Nature Chemical Biology. If the results hold up in humans, one of these metabolites, which has not previously been associated with neuropathic pain, could potentially serve as both a molecular indicator of and therapeutic target for the condition, for which few treatment options exist. Read more...
German Society for Gene Therapy "Perspective in Cell and Gene-Based Medicine" Congress, Frankfurt (Main) March 15th – 17th , 2012
January 20th, 2012
"The three-parent family: this is another attempt to dehumanise disabled people"

Lorenzo & Augusto Odone Cristina Odone
Cristina Odone is a journalist, novelist and broadcaster specialising in the relationship between society, families and faith. She is a Research Fellow at the Centre for Policy Studies and is a former editor of the Catholic Herald and deputy editor of the New Statesman. She is married and lives in west London with her husband, two stepsons and a daughter.
January 11th, 2012
ByAlex Planes, The Motley FoolPosted 3:54PM 01/11/12Investing
The relentless march of genome sequencing technology continued this week, right on target. When I wrote aboutthe race to the $1,000 genomelate last year, I had no idea that the two largest sequencing companies would so soon unveil machines capable of offering just that, but I knew it was coming. Now that it's here, what does it mean for the future of medicine -- and the future of the planet? More than you might think.
|
|
|